Pricing Log in Create free account
Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue
+10.6%
EPS
−104.4%
Free cash flow
−69.3%
Total debt
+16.0%

Quarter to September 2026, against a year earlier

248.43 4.50 +1.84%
Market cap
$36.1B
P/E
104×
Fwd P/E
47.4×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Biogen Inc. 10-Q filed Jul 31, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 6:05 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: 80 added · 17 removed · 88 modified; 25 with only figures updated; 2 moved without change

  1. Modified · INTRODUCTION

    Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; QALSODY for the treatment of ALS; and FUMADERMQALSODY for the treatment of severe plaque psoriasisALS.